דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים: Brainstorm Cell (BCLI)

Brainstorm Cell (BCLI) is developing cell therapy to combat ALS in Israel and the US. The trailing twelve months (TTM) operating revenue growth reflects the business dynamics, with the current figure standing at 0.00. Scaling is limited by manual production, which is offset by the product's high price. However, the lack of revenue and FDA denials for accelerated therapy approval create critical financial risks for the company.

Fundamental asset selection requires analyzing trailing twelve-month revenue dynamics to separate short-term noise from sustainable operational trends. This metric measures the percentage deviation of current sales from the same period last year, which allows Brainstorm Cell (BCLI) to assess the commercialization pace of the NurOwn platform via the TTM sales volume change indicator.